



KINEXUS

Kinexus Announces Launch of KiNET Functional Proteomics Database

Proprietary Cell Signaling Database Designed with Bioinformatics Capabilities

FOR IMMEDIATE RELEASE NOVEMBER 16, 2005

VANCOUVER, British Columbia – Kinexus Bioinformatics Corporation, the world-leader in tracking key cell communication proteins, announced today the availability of its first Internet accessible, cell signaling proteomics database (KiNET) with built in bioinformatics searching capabilities. KiNET is the world's only functional proteomics database available to the health care research community and features over 200,000 measurements of the expression levels and phosphorylation states of hundreds of signal transduction proteins from hundreds of different biological specimens, including over 200 tumor cell lines. The proteins tracked in KiNET are critical for the operation of all cell and tissue types, as their malfunction has been linked to over 400 diseases including cancer, cardiovascular and neurodegenerative diseases. Subscribing clients are able to search KiNET to plan out their next research project, discover potential drug targets and biomarkers for disease, or to better understand which pathways are regulated in response to various drugs and other treatments.

“The highly unique dataset contained in KiNET has been collected from the results of our Kinetworks™ immunoblotting services performed over the last 6 years, at a cost of over 8 million dollars,” said Dr. Steven Pelech, President and Founder of Kinexus and a Professor at the University of British Columbia. “Over 95% of the KiNET data is unpublished and not available elsewhere. It was produced in-house using the same reagents and methodology by our highly experienced scientists and technicians to ensure that it is fully comparable.” The goal of Kinexus since its inception in 1999 has been to provide the biomedical research community with the ability to simultaneously track hundreds of key communication proteins to facilitate understanding of normal and disease processes at the molecular level. Several pharmaceutical companies have expressed an interest in licensing the KiNET database in-house.

KiNET can be queried for the regulation of a target protein in hundreds of well defined experimental model systems, or a treatment or cell/tissue type can be interrogated for changes in the expression and phosphorylation of hundreds of different signaling proteins. In addition to offering KiNET to the general public, Kinexus intends to mine the database for interesting drug targets and disease biomarkers.

Kinexus is a private, biopharmaceutical company engaged in the research and development of innovative methods to uncover the relationships between signaling proteins in cellular communication networks. The application of this knowledge positions Kinexus and its clients to advance drug development, disease diagnosis and personalized therapies to improve human health.

**For further information, please contact Kinexus Bioinformatics Corporation
toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca**

PRESS RELEASE - NOVEMBER 16, 2005